HIV-1-infection Completed Phase 3 Trials for Bictegravir (DB11799)

Also known as: HIV -1 Infection / HIV1 Infection / HIV-I Infection / HIV 1 Infection / Human Immunodeficiency Virus Type 1 (HIV-1) Infection / Human Immunodeficiency Virus I Infection / Infection, Human Immunodeficiency Virus I / HIV-1 Infections / HIV-1 Infection / [X]Human immunodeficiency virus disease (disorder) / Human immunodeficiency virus [HIV] disease / [X]Unspecified human immunodeficiency virus [HIV] disease (disorder) / HIV disease / (AIDS) or (HIV infection) / HTLV-III/LAV infection -RETIRED- / HIV infection NOS / Human immunodeficiency virus syndrome / Human immunodeficiency virus infection, unspecified / HIV Infections / HIV infection / Human immunodeficiency virus infection (disorder)

IndicationStatusPhase
DBCOND0054009 (HIV-1-infection)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02603107Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected AdultsTreatment
NCT02603120Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically SuppressedTreatment
NCT02652624Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected WomenTreatment
NCT02600819Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic HemodialysisTreatment